These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28595486)

  • 1. Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis.
    McCarthy MW; Walsh TJ
    Expert Rev Respir Med; 2017 Sep; 11(9):739-748. PubMed ID: 28595486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study.
    Hoenigl M; Prattes J; Neumeister P; Wölfler A; Krause R
    Mycoses; 2018 Mar; 61(3):201-205. PubMed ID: 29112326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
    Miceli MH; Kauffman CA
    Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The spectrum of pulmonary aspergillosis.
    Kanj A; Abdallah N; Soubani AO
    Respir Med; 2018 Aug; 141():121-131. PubMed ID: 30053957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
    Petraitis V; Petraitiene R; Katragkou A; Maung BBW; Naing E; Kavaliauskas P; Barat S; Borroto-Esoda K; Azie N; Angulo D; Walsh TJ
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32179521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.
    Perfect JR; Cornely OA; Heep M; Ostrosky-Zeichner L; Mullane KM; Maher R; Croos-Dabrera R; Lademacher C; Engelhardt M; Chen C; Marty FM
    Mycoses; 2018 Jul; 61(7):420-429. PubMed ID: 29570857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.
    Lepak AJ; Marchillo K; Vanhecker J; Andes DR
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6284-9. PubMed ID: 24100500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole].
    Garcia-Vidal C
    Rev Iberoam Micol; 2018; 35(4):192-197. PubMed ID: 30455108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
    Petraitis V; Petraitiene R; Moradi PW; Strauss GE; Katragkou A; Kovanda LL; Hope WW; Walsh TJ
    Antimicrob Agents Chemother; 2016 May; 60(5):2718-26. PubMed ID: 26883703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.
    Kovanda LL; Maher R; Hope WW
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):887-97. PubMed ID: 27160418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
    Livermore J; Hope W
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):759-65. PubMed ID: 22530880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response.
    Krel M; Petraitis V; Petraitiene R; Jain MR; Zhao Y; Li H; Walsh TJ; Perlin DS
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3373-8. PubMed ID: 24687510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.
    Petraitis V; Petraitiene R; McCarthy MW; Kovanda LL; Zaw MH; Hussain K; Shaikh N; Maung BBW; Sekhon NK; Hope WW; Walsh TJ
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isavuconazole: Case Report and Pharmacokinetic Considerations.
    Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
    Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Treatment of Chronic Pulmonary Aspergillosis With Isavuconazole.
    Guillen Vera D; Ruiz Ruigómez M; García Moguel I; Morales Ruiz R; Corbella L; Fernández Rodríguez C
    J Investig Allergol Clin Immunol; 2019; 29(6):459-460. PubMed ID: 31172952
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute Invasive Pulmonary Aspergillosis: Clinical Presentation and Treatment.
    Heylen J; Vanbiervliet Y; Maertens J; Rijnders B; Wauters J
    Semin Respir Crit Care Med; 2024 Feb; 45(1):69-87. PubMed ID: 38211628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
    Ananda-Rajah MR; Kontoyiannis D
    Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.
    Shirley M; Scott LJ
    Drugs; 2016 Nov; 76(17):1647-1657. PubMed ID: 27766566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Invasive aspergillosis in solid organ transplantation].
    Silva JT; Torre-Cisneros J; Aguado JM
    Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary aspergillosis: recent advances.
    Thompson GR; Patterson TF
    Semin Respir Crit Care Med; 2011 Dec; 32(6):673-81. PubMed ID: 22167395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.